OVARIAN CANCER

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Patients with malignant ovarian tumor when treatment is late (> Phase II), ovarian cancer is the surgical treatment called tumor or cytoreductive surgery or large resection.
Surgery is to do everything possible to the original tumor resection and can see the pots, peritoneal metastasis, so that each region of residual lesion diameter of less than 2.0 cm to 1.5 cm. Intraoperative from ascites fluid or cells for blood screening. Because ovarian and uterine cancer often, the annex or visco-invasion, peritoneal and keep pots, it is more of "carpet-volume" or "dumplings", from extraperitoneal space elements from the peritoneal wall, bladder and pelvic floor serous peritoneal, along with the uterus and pelvic peritoneum block tumor resection. The pots have peritoneal metastasis tissues or organs should be possible to complete resection or partial resection, resection of the omentum, some intestinal resection, resection of the bladder or ureter shifting values. The removal of the tumor as possible aim is to enhance postoperative radiotherapy and chemotherapy effect. The merger of ovarian cancer ascites, regardless of whether all resection are advised to intraperitoneal indwelling catheter for intraperitoneal injection of anti-cancer drugs. Anti-cancer drugs or radioisotopes for preparation also can be injected directly unresectable tumors.
Surgery can not decide in its benign and malignant ovarian tumor resection specimens should be admitted or contralateral ovarian tissue frozen tablets sent for histopathologic examination. There is no such conditions, generally after the contralateral normal ovarian As can be temporarily retained, pathological specimens were sent checks to clear in nature, and close observation. The previous suspected metastatic ovarian tumor and failed to find its source, should be in operation in detail in the original exploration of abdominal lesions, after further treatment for reference.

Tags: abdominal, annex, anti, benign, blood, cancer, cause, cell, cells, chemotherapy, drug, drugs, eat, examination, exploration, gene, injection, intraperitoneal, malignant, metastasis, metastatic, ovarian, patients, pelvic, radiotherapy, resection, residual, screening, surgery, surgical, therapy, treatment, tumor, tumors, uterine

Ovarian cancer

Tags: age, annex, blood, body, cancer, cases, cell, cells, chemotherapy, clinical, cyst, cystic, diagnosis, drug, drugs, early, eat, examination, fat, mass, method, ovarian, pain, patients, pelvic, poor, prognosis, reduce, resection, study, surgical, symptoms, therapy, time, toxicity, treatment, tumor, tumors, women

Disease Overview

Tags: age, breast, cancer, carcinoma, cause, cell, cells, chemotherapy, children, diagnosis, early, eat, ert, fat, gene, group, incidence, increased, knowledge, life, lymph, malignant, metastatic, ovarian, patients, preventive, radiotherapy, rate, risk, second, surface, surgery, survival, symptoms, tea, therapy, time, treatment, tumor, tumors, uterine, women

Basic symptoms: early ovarian cancer usually no obvious symptoms, if there is non-specific symptoms, such as menstrual disorder, mild gastrointestinal discomfort. With the growth of tumors may arise under bloating, discomfort, or sometimes because of oppression involved in the bladder or rectum and frequency, diarrhea, constipation,. More advanced symptoms from ascites, omental or metastatic gastrointestinal such as abdominal distension, shortness of breath, abdominal discomfort, and incomplete intestinal obstruction or even obstructive symptoms. Part of mesenchymal tumors or tumor invasion of genistein and uterus can cause irregular vaginal bleeding. If a tumor metastasis may have different performance of the corresponding organ involvement.

Tags: abdominal, age, bleeding, blood, cancer, cause, cell, chemotherapy, cyst, cystic, diagnosis, early, eat, ert, examination, gene, grams, growth, gynecological, injection, knowledge, malignant, mass, metastasis, metastatic, oppression, ovarian, patients, pelvic, prognosis, radiotherapy, residual, screening, staging, surgery, symptoms, therapy, time, treatment, tumor, tumors, usually

Epithelial ovarian cancer in the United States is a relatively rare in Gynecologic Oncology, 2004, there were approximately 25,580 cases of new onset patients, 16,090 cases patients died. The majority of patients with advanced cancer, treatment for surgical resection and postoperative to platinum-based chemotherapy. During the past 10 years, chemotherapy improved survival rates improve, and recurrent tumor treatment more effective. In addition, the genetic risk factors for making in-depth understanding of the prevention strategy to become individualized approach to bilateral tubal women - ovarian surgery. This report summarized the clinical characteristics of epithelial ovarian, after reports focus on the treatment of the latest developments.

Tags: age, brca1, breast, cancer, carcinoma, cases, cause, chemotherapy, clinical, diagnosis, drug, drugs, early, eat, ert, estrogen, examination, family, gene, group, groups, history, incidence, increased, life, malignant, mutation, ovarian, ovary, patients, pelvic, preventive, protein, rate, reduce, resection, risk, screening, second, study, surface, surgery, surgical, survival, syndrome, therapy, time, treatment, tumor, usually, women

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Austria adopted interferon combination of chemotherapy and women's ovarian cancer treatment, and achieved better than chemotherapy alone effect.

Austrian University of Innsbruck gynecological experts led by Professor Christian Anmaerte a Gynecologic Oncology Group study started three years ago one of the study. Their 148 already one ovarian cancer surgery in women with a combination of chemotherapy for the treatment of interferon test. Six patients received treatment three times a week in treatment, and the other a comparison group of patients is only chemotherapy. Results of 51% in patients treated with interferon did not recur tumor, and comparison group only 38% of patients with tumors did not recur.

Tags: blood, body, cancer, cell, cells, chemotherapy, eat, ert, group, growth, gynecological, interferon, ovarian, patients, protein, study, surgery, therapy, time, treatment, tumor, tumors, women

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Ovarian cancer

Tags: abdominal, age, body, cancer, cause, cell, cells, chemotherapy, clinical, days, early, eat, ert, examination, family, gene, grams, gynecological, life, ovarian, patients, pelvic, poor, quality, radiotherapy, surgery, surgical, survival, symptoms, therapy, treatment, tumor, women